" Liquid biopsies â€” blood tests that can detect circulating tumor DNA â€” could help detect cancer more accurately, guide individualized therapy, and better monitor patients' progress during treatment if they live up to their promise, said expe"...
ZARXIO is produced by Escherichia coli (E coli) bacteria into which has been inserted the human granulocyte colony-stimulating factor gene. ZARXIO has a molecular weight of 18‚800 daltons. The protein has an amino acid sequence that is identical to the natural sequence predicted from human DNA sequence analysis‚ except for the addition of an N-terminal methionine necessary for expression in E coli. Because ZARXIO is produced in E coli‚ the product is nonglycosylated and thus differs from G-CSF isolated from a human cell.
ZARXIO injection is a sterile‚ clear‚ colorless to slightly yellowish‚ preservative-free liquid containing filgrastim-sndz at a specific activity of 1.0 x 108 U/mg (as measured by a cell mitogenesis assay). The product is available in single-dose prefilled syringes. The single-dose prefilled syringes contain either 300 mcg/0.5 mL or 480 mcg/0.8 mL of filgrastimsndz. See Table 4 below for product composition of each single-dose prefilled syringe.
Table 4. Product Composition
|300 mcg/0.5 mL Syringe||480 mcg/0.8 mL Syringe|
|Filgrastim-sndz||300 mcg||480 mcg|
|Glutamic Acid||0.736 mg||1.178 mg|
|Polysorbate 80||0.02 mg||0.032 mg|
|Sorbitol||25 mg||40 mg|
|Water for Injection USP q.s. ad*||ad 0.5 mL||ad 0.8 mL|
|*quantity sufficient to make|
Last reviewed on RxList: 3/2/2017
This monograph has been modified to include the generic and brand name in many instances.
Additional Zarxio Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.